Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Operating Leases (2018 - 2025)

Cytosorbents' Operating Leases history spans 8 years, with the latest figure at $11.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $11.9 million for Q4 2025, down 4.35% from a year ago — trailing twelve months through Dec 2025 was $11.9 million (down 4.35% YoY), and the annual figure for FY2025 was $11.9 million, down 4.35%.
  • Operating Leases for Q4 2025 was $11.9 million at Cytosorbents, down from $12.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $13.5 million in Q2 2022 to a low of $461064.0 in Q1 2021.
  • The 5-year median for Operating Leases is $13.0 million (2022), against an average of $12.2 million.
  • The sharpest move saw Operating Leases decreased 12.56% in 2021, then skyrocketed 2756.95% in 2022.
  • Year by year, Operating Leases stood at $13.3 million in 2021, then fell by 0.82% to $13.1 million in 2022, then dropped by 1.87% to $12.9 million in 2023, then fell by 3.51% to $12.4 million in 2024, then dropped by 4.35% to $11.9 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $11.9 million, $12.1 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.